共 50 条
- [1] Trial in progress: A phase 1b single-arm, open-label, study of emavusertib (CA-4948) in combination with azacitidine and venetoclax in acute myeloid leukemia patients in complete response with measurable residual diseaseCANCER RESEARCH, 2024, 84 (07)von Roemeling, ReinhardDe La Fuente, AdolfoCerchione, ClaudioScholl, SebastianMiddeke, Jan MoritzChoudhary, Gaurav S.Lamar, MariaAngelides, StevenPlatzbecker, Uwe
- [2] A phase 1 single-arm, open-label study of emavusertib (CA-4948) in combination with azacitidine and venetoclax in patients (pts) with acute myeloid leukemia (AML) in complete response (CR) with measurable residual disease (MRD).JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)de la Fuente Burguera, AdolfoCerchione, ClaudioScholl, SebastianMiddeke, Jan MoritzNitika, NitikaLane, Maureen E.Zhao, WanyingAngelides, Stevenvon Roemeling, ReinhardPlatzbecker, Uwe
- [3] TRIALS IN PROGRESS: A PHASE 1B SINGLE-ARM, OPEN-LABEL STUDY OF EMAVUSERTIB IN COMBINATION WITH AZACITIDINE AND VENETOCLAX IN AML PATIENTS IN COMPLETE RESPONSE WITH MRDBONE MARROW TRANSPLANTATION, 2024, 59 : 182 - 182de la Fuente, AdolfoCerchione, ClaudioScholl, SebastianMiddeke, Jan MoritzChoudhary, Gaurav S.Ferrari, Doravon Roemeling, ReinhardPlatzbecker, Uwe
- [4] Efficacy and safety of venetoclax in combination with cytarabine and azacitidine (VAA) in relapsed/refractory acute myeloid leukemia: An open-label, single-arm, phase II study.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)You, LiangshunLiu, YiMai, WenyuanZhou, DeXie, WanzhuoMao, LipingZhou, XinpingTong, HongyanJin, JieMeng, Haitao
- [5] Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemiaBLOOD ADVANCES, 2024, 8 (03) : 591 - 602Lane, Andrew A.Garcia, Jacqueline S.Raulston, Evangeline G.Garzon, Jada L.Galinsky, IleneBaxter, Emilie W.Leonard, RebeccaDeangelo, Daniel J.Luskin, Marlise R.Reilly, Christopher R.Stahl, MaximilianStone, Richard M.Vedula, Rahul S.Wadleigh, Martha M.Winer, Eric S.Mughal, TariqBrooks, ChristopherV. Gupta, IraStevenson, Kristen E.Neuberg, Donna S.Ren, SiyangKeating, JuliaKonopleva, MarinaSten, AnthonyPemmaraju, Naveen
- [6] High efficacy of Azacitidine plus HAG in acute myeloid leukemia: an open-label, single-arm, multi-center, phase 2 studyBlood Cancer Journal, 12Jun LiQi HanYanqing HuangYanhui WeiJie ZiLidong ZhaoZhimei CaiXuzhang LuRong XiaoYanming ZhangXiaotian YangHao XuNaitong SunWanchuan ZhuangZhengdong WuYuan XiaYanli XuBin HeWei ZhuFengling MinYongchun ChenBanghe DingPeimin ShiJing XieHua TangZefa LiuBingzong LiYu SunHongxia QiuLimin DuanElanora DovatChunhua SongLaszlo SzeKelySinisa DovatZheng Ge
- [7] High efficacy of Azacitidine plus HAG in acute myeloid leukemia: an open-label, single-arm, multi-center, phase 2 studyBLOOD CANCER JOURNAL, 2022, 12 (10)Li, JunHan, QiHuang, YanqingWei, YanhuiZi, JieZhao, LidongCai, ZhimeiLu, XuzhangXiao, RongZhang, YanmingYang, XiaotianXu, HaoSun, NaitongZhuang, WanchuanWu, ZhengdongXia, YuanXu, YanliHe, BinZhu, WeiMin, FenglingChen, YongchunDing, BangheShi, PeiminXie, JingTang, HuaLiu, ZefaLi, BingzongSun, YuQiu, HongxiaDuan, LiminDovat, ElanoraSong, ChunhuaSzeKely, LaszloDovat, SinisaGe, Zheng
- [8] Safety and Efficacy of Cusatuzumab in Combination with Venetoclax and Azacitidine (CVA) in Patients with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Eligible for Intensive Chemotherapy; An Open-Label, Multicenter, Phase 1b StudyBLOOD, 2021, 138Roboz, Gail J.Pabst, ThomasAribi, AhmedBrandwein, Joseph M.Dohner, HartmutFiedler, WalterGandini, DomenicaGeddes, MichelleHou, Jing-ZhouHowes, Angela J.Hultberg, AnnaHuselton, EricJacobs, JulieKane, ColleenLech-Maranda, EwaLouwers, MariekeNottage, KerriPlatzbecker, UweRampal, RaajitSalman, MariyaShah, PriyaStevens, DonStuart, MonicSubklewe, MarionSumbul, AnneWang, Eunice S.Wierzbowska, AgnieszkaYao, BinYee, KarenKantarjian, HagopBorthakur, Gautam
- [9] Phase 1/2a study of the IRAK4 inhibitor CA-4948 as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed/refractory (R/R) acute myeloid leukemia or lyelodysplastic syndrome.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Garcia-Manero, GuillermoWiner, Eric S.DeAngelo, Daniel J.Tarantolo, Stefano R.Sallman, David AndrewDugan, JamesGroepper, StefanieGiagounidis, AristotelesGotze, Katharina S.Metzeler, KlausLi, Chia-ChengZhou, LiMartinez, ElizabethLane, Maureen E.Von Roemeling, Reinhard W.Bohme, MatthiasKubasch, Anne SophieVerma, Amit K.Platzbecker, Uwe
- [10] Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II studyBlood Cancer Journal, 11Patrick K. RevilleHagop M. KantarjianFarhad RavandiElias JabbourCourtney D. DiNardoNaval DaverNaveen PemmarajuMaro OhanianYesid AlvaradoLianchun XiaoGheath AlatrashSanam LoghaviCaitlin R. RauschGautam BorthakurMarina KonoplevaJorge CortesTapan M. Kadia